RT Journal Article SR Electronic T1 Neurodevelopmental disorders associated variants in ADAT3 disrupt the activity of the ADAT2/ADAT3 tRNA deaminase complex and impair neuronal migration JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.03.01.24303485 DO 10.1101/2024.03.01.24303485 A1 Del-Pozo-Rodriguez, Jordi A1 Tilly, Peggy A1 Lecat, Romain A1 Vaca, Hugo Rolando A1 Mosser, Laureline A1 Balla, Till A1 Gomes, Marina Vitoria A1 Ramos-Morales, Elizabeth A1 Brivio, Elena A1 Salinas-Giégé, Thalia A1 VanNoy, Grace A1 England, Eleina M. A1 Lovgren, Alysia Kern A1 O’Leary, Melanie A1 Chopra, Maya A1 Gable, Dustin A1 Alnuzha, Aisha A1 Kamel, Mona A1 Almenabawy, Nihal A1 O’Donnell-Luria, Anne A1 Neil, Jennifer E. A1 Gleeson, Joseph G. A1 Walsh, Christopher A. A1 Elkhateeb, Nour A1 Selim, Laila A1 Srivastava, Siddharth A1 Nedialkova, Danny D. A1 Drouard, Laurence A1 Romier, Christophe A1 Bayam, Efil A1 Godin, Juliette D. YR 2024 UL http://medrxiv.org/content/early/2024/03/05/2024.03.01.24303485.abstract AB The ADAT2/ADAT3 complex catalyzes the adenosine to inosine modification at the wobble position of eukaryotic tRNAs. Mutations in ADAT3, the catalytically inactive subunit of the ADAT2/ADAT3 complex, have been identified in patients presenting with severe neurodevelopmental disorders (NDDs). Yet, the physiological function of ADAT2/ADAT3 complex during brain development remains totally unknown. Here we showed that maintaining a proper level of ADAT2/ADAT3 catalytic activity is required for correct radial migration of projection neurons in the developing mouse cortex. In addition, we not only reported 7 new NDD patients carrying biallelic variants in ADAT3 but also deeply characterize the impact of those variants on ADAT2/ADAT3 structure, biochemical properties, enzymatic activity and tRNAs editing and abundance. We demonstrated that all the identified variants alter both the expression and the activity of the complex leading to a significant decrease of I34 with direct consequence on their steady-state. Using in vivo complementation assays, we correlated the severity of the migration phenotype with the degree of the loss of function caused by the variants. Altogether, our results indicate a critical role of ADAT2/ADAT3 during cortical development and provide cellular and molecular insights into the pathogenicity of ADAT3-related neurodevelopmental disorder.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from INSERM (ATIP-Avenir program, J.D.G.), the French state funds through the Agence Nationale de la Recherche (ANR-21-CE12-0026 to J.D.G., C.R. and L.D.; ANR-DFG ANR-19-CE16-0023 to J.D.G. and D.D.N.; ANR-10-IDEX-0002-02 and ANR-10-LABX-0030-INRT to J.D.G. and C.R.), ERC CoG 2021 TransNeuroFate (J.G.), SFRI-STRAT′US project [ANR 20-SFRI-0012]; and EUR IMCBio [ANR-17-EURE-0023]), INSERM/CNRS (J.D.G., C.R, and L.D.) and University of Strasbourg (J.D.G., C.R., and L.D.). D.D.N. is funded by the Max Planck Society, the European Research Council under the European Union′s Horizon 2020 Research and Innovation Programme (ERC Starting Grant 803825-TransTempoFold) and the EMBO Young Investigator Program (YIP 4833). E.B. was supported by INSERM, Fondation Jerome Lejeune and ANR. R.L. is supported by Ministère de l'Enseignement Supérieur de la Recherche et de l'Innovation. E.Br is supported by Fondation pour la recherche médicale. P.T. is research assistant at the University of Strasbourg. C.R. is a CNRS investigator. J.D.G. is an INSERM investigator. Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Patient 5, 6, 7) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. CAW is supported by a grant from the NINDS (RO1 NS35129) and is an Investigator of the Howard Hughes Medical Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Inclusion and genetic studies were approved by the ethics committee of the Broad Institute of MIT, Boston, USA, of Cairo University Faculty of Medicine Research, Boston Children's Hospital, the University of California, San Diego, USA and the Cambridge University Hospital, Cambridge, UK. All participants or their legal representatives gave their consent to take part in the present study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding authors.